---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-027949"
form_type: "8-K"
ticker: "MYO"
cik: "0001369290"
company_name: "MYOMO, INC."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:18:37.246854+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Myomo Q4 revenue $4.8M (+18% YoY), backlog record 230 units, guides FY2024 rev $28M-$30M

## Summary
- Q4 product revenue $4.756M (+18% YoY); recognized 107 MyoPro units (+6%).
- Net loss $2.5M ($0.07/shr) vs $2.2M ($0.29/shr) in Q4 2022; adjusted EBITDA -$2.1M.
- Record backlog 230 units (+40% YoY), including 44 Medicare Part B patients receiving rental payments or qualified.
- Q1 2024 revenue guidance $4.1M-$4.3M; full year 2024 revenue target $28M-$30M with operating cash flow breakeven targeted by Q4.
- CMS finalized HCPCS fees for MyoPro codes L8701 ($33,480.90) and L8702 ($65,871.74) effective April 1, 2024.

## SEC filing metadata
- accession: 0000950170-24-027949
- form_type: 8-K
- ticker: MYO
- cik: 0001369290
- company_name: MYOMO, INC.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369290/000095017024027949/0000950170-24-027949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369290/000095017024027949/myo-20240307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-027949
- JSON: https://secwatch.observer/filing/0000950170-24-027949.json
- Plain text: https://secwatch.observer/filing/0000950170-24-027949.txt

## Key facts
- Earnings Releases
  MYOMO, INC. reported the three months and year ended December 31, 2023 results: revenue $4.8 million, net income $0.07 per share. Guidance initiated.
  - Period: the three months and year ended December 31, 2023
  - Revenue: $4.8 million
  - Net income: $0.07 per share
  - Guidance: initiated
  - Result: reported results
  source text: by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2023 Financial Results Q4 total revenue of $4.8 million, up 18% over the prior year Addition of Medicare Part B patients to backlog results in record 183 MyoPro orders and insurance authorizations received in Q4, up 87% over the prior
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369290/000095017024027949/0000950170-24-027949-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.